Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1338 • ACR Convergence 2023
The Advantage of Tight Control and Treat-to-Target in New-onset Rheumatoid Arthritis Patients in Daily Rheumatology Practice: Results from a Contemporary University Clinic Inception Cohort
Katarina Friberger Pajalic¹, Jon Thorkel Einarsson¹, Caroline Bengtsson², Ellen Landgren³, Elisabeth Mogard⁴, Carmen Roseman⁵, Johan Karlsson Wallman⁴, Elisabet Lindqvist⁴, Tor Olofsson⁴ and Meliha Kapetanovic⁴, ¹Lund University, Institution for clinical sciences, section for rheumatology Lund and Lund University Hospital, Lund, Sweden, ²Lund University Hospital, section for rheumatology, Lund, Sweden, ³Lund University, Institution for clinical sciences, section for rheumatology Lund and Skåne University Hospital, Lund, Sweden, ⁴Lund University and Skåne University Hospital, Lund, Sweden, ⁵Lund University, Institution for clinical sciences, section for rheumatology Lund and Lund University Hospital, Lund, Sweden
Background/Purpose: Since 2018, all patients with new-onset rheumatoid arthritis (RA) at the Department of Rheumatology, Skåne University Hospital, Lund, Sweden, are invited to participate in…
Abstract Number: 1627 • ACR Convergence 2023
Methotrexate Use Associates with Ischemic Cardiovascular Risk Reduction in Males but Not Females with Rheumatoid Arthritis
George Karpouzas¹, Sarah Ormseth², Piet Van Riel³, Elena Myasoedova⁴, Miguel A Gonzalez-Gay⁵, Alfonso Corrales⁶, Solbritt Rantapää-Dahlqvist⁷, Petros Sfikakis⁸, Patrick Dessein⁹, Linda Tsang⁹, Carol Hitchon¹⁰, Hani El Gabalawi¹⁰, Virginia Pascual Ramos¹¹, Irazú Contreras Yañez¹², Iris Colunga¹³, Dionicio A. Galarza-Delgado¹³, José Ramón Azpiri-López¹³, Silvia Rolefstad¹⁴, Anne Grete Semb¹⁵, Durga P Misra¹⁶, GEORGE KITAS¹⁷ and Ellen Margrethe Hauge¹⁸, ¹Harbor-UCLA Medical Center, Torrance, CA, ²The Lundquist Institute, Torrance, CA, ³Radboud University Medical Center, Drunen, Netherlands, ⁴Mayo Clinic, Rochester, MN, ⁵IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain, ⁶Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ⁷Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ⁸National Kapodistrian University of Athens Medical School, Athens, Greece, ⁹University of Witwatersrand, Johannesburg, South Africa, ¹⁰University of Manitoba, Winnipeg, MB, Canada, ¹¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ¹²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ¹³Hospital Universitario UANL, Monterrey, Mexico, ¹⁴Diakonhjemmet Hospital, Oslo, Norway,, Oslo, Norway, ¹⁵Preventive Cardio-Rheuma clinic, Dept Rheum, Diakonhjemmet Hospital, Oslo, Norway, ¹⁶Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ¹⁷The Dudley Group NHS Foundation Trust, Birmingham, United Kingdom, ¹⁸Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Patients with rheumatoid arthritis (RA) experience higher cardiovascular risk compared to non-inflammatory disease controls. Methotrexate (MTX) may decrease cardiovascular risk in patients with RA.…
Abstract Number: 1720 • ACR Convergence 2023
Successful Treatment of Rheumatoid Arthritis in Mice Using Cenerimod, a Selective Modulator of the S1P1 Receptor, Demonstrates the Potential Benefits of S1P1 Receptor Immunomodulation for Rheumatic Diseases
Thomas Hoyler, Maxime Bulle, Conrad Wyss, Jeremy Scherer, Sylvie Froidevaux and Marianne Martinic, Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland
Background/Purpose: Discovery of the essential role of S1P signaling in regulating lymphocyte trafficking led to the development of S1P receptor modulators for the treatment of…
Abstract Number: 1739 • ACR Convergence 2023
Mass Spectrometry Identified Rheumatoid Arthritis-Specific Modified Proteins and the Discovery of Antigen-Specific Hidden Autoantibodies
Khetam Ghannam¹, Marieluise Kirchner², Holger Bang³, Thomas Häupl⁴, Sarah Ohrndorf¹, Jan Zernicke¹, Ulrike Kuckelkorn⁵, Philipp Mertins⁶, Eugen Feist⁷ and Gerd Burmester⁸, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Proteomics Platform at Max Delbrück Center for Molecular Medicine and Berlin Institute of Health (BIH), Berlin, Germany, ³Orgentec Diagnostika GmbH, Mainz, Germany, ⁴Helios Department of Rheumatology, Vogelsang-Gommern, Germany, ⁵Institute of Biochemistry, Berlin, Germany, ⁶Proteomics Platform at Max Delbrück Center for Molecular Medicine and Berlin Institute of Health (BIH), Berlin, Germany, ⁷Helios Department of Rheumatology and Clinical Immunology, Vogelsang-Gommern, Germany, ⁸Charité – Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany
Background/Purpose: Rheumatoid arthritis (RA) is a chronic and systemic autoimmune disease characterized by synovial inflammation and progressive joint destruction. Given the presumed pathophysiologic role of…
Abstract Number: 1755 • ACR Convergence 2023
Unique Pattern of Cadherin 6 Localization in Fibroblast-Like Synoviocytes
Camilla R. L. Machado¹, David Boyle¹, Narayanan B. Perumal², Robert J. Benschop³ and Gary Firestein¹, ¹University of California San Diego, San Diego, CA, ²Eli Lilly and Company, San Diego, CA, ³Eli Lilly and Company, Indianapolis, IN
Background/Purpose: The synovial lining of rheumatoid arthritis (RA) is formed by a network of fibroblast-like synoviocytes (FLS). Cadherins are type I transmembrane proteins and participate…
Abstract Number: 1771 • ACR Convergence 2023
Role of Periostin in the Pathophysiology and Accurate Diagnosis of Interstitial Lung Disease Associated with Autoimmune Diseases
Verónica Pulito-Cueto¹, David Iturbe-Fernández², Victor Mora-Cuesta², Joao Carlos Batista-Liz¹, Belén Atienza-Mateo³, María Sebastián-Mora¹, Virginia Portilla¹, Alfonso Corrales¹, Miguel A Gonzalez-Gay⁴, Jose Cifrian⁵, Ricardo Blanco¹ and Raquel López-Mejías¹, ¹Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ²Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital, Santander, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain, ⁵Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital; School of Medicine, Cantabria University, Santander, Spain
Background/Purpose: Periostin is an extracellular matrix protein that contributes to the development and repair of lung tissue [1]. Previous works have described periostin as a…
Abstract Number: 1885 • ACR Convergence 2023
The Frequency and Importance of Subchondral Radius Cysts in Rheumatoid Arthritis Patients Under B/tsDMARDs
Umut Kalyoncu¹ and Gizem Ayan², ¹Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ²Hacettepe University Faculty of Medicine Division of Rheumatology, Ankara, Turkey
Background/Purpose: The presence of subchondral cysts in patients with rheumatoid arthritis (RA) has long been recognised. The concept of geodes used in geology would be…
Abstract Number: 2033 • ACR Convergence 2023
Sex Differences in Patient-Reported Outcomes in Patients with Rheumatoid Arthritis After Starting a New Disease-Modifying Antirheumatic Medication
John Davis¹, Sara Achenbach², Courtney Arment¹, Delamo Bekele¹, Vanessa Kronzer¹, Thomas Mason¹, Elena Myasoedova¹, Lynne Peterson¹, Kerry Wright¹ and Cynthia Crowson¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, Rochester, MN
Background/Purpose: Patient-Reported Outcome Measurement Information System (PROMIS®) measures are valued in the assessment of health outcomes for patients with rheumatoid arthritis (RA). However, little is…
Abstract Number: 2109 • ACR Convergence 2023
Real-world Positivity of 14-3-3η Protein in Rheumatoid Arthritis
Roshan Subedi¹, Massiel Jimenez Artiles², Adnan Al Najada², Afrah Misbah², Qi Wang³, Alexander Kusnik², Zhiting Tang², Syed Mohammed Faizaan Zabiullah² and Anthony Ocon⁴, ¹Rochester Regional Health/Unity Hospital, Greece, NY, ²Rochester Regional Health, Rochester, NY, ³Rochester Regional Health/Unity Hospital, Rochester, NY, ⁴Rochester Regional Health, Fairport, NY
Background/Purpose: 14-3-3η protein may be elevated in the blood of inflammatory arthritis patients. It is a commercially available novel biomarker used to aid in the…
Abstract Number: 2125 • ACR Convergence 2023
Comparing the ITIS Diet and the Mediterranean Diet in Rheumatoid Arthritis: Preliminary Findings on Clinical and Microbiome Outcomes
Marta Sala Climent¹, Martha Cedeno¹, Roxana Coras², Tiffany Holt¹, Soo-In Choi³, Abha Singh⁴, Katherine Nguyen Nguyen⁵, Susan Lee¹, Simone Zuffa Zuffa¹, Meritxell Agustin-Perez¹, Marta Fernandez-Bustamante¹, Shahrokh Golshan¹, Arthur Kavanaugh⁶ and Monica Guma⁵, ¹University of California San Diego, San Diego, CA, ²Cedars-Sinai Medical Center, Los Angeles, CA, ³University of California San Diego, Alicante, CA, ⁴Department of Medicine, University of California San Diego, La Jolla, CA, ⁵University of California San Diego, La Jolla, CA, ⁶University of California San Diego, School of Medicine, Riverside, CA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic condition characterized by persistent joint inflammation, functional impairment, and disability. Adhering to a Western diet has been associated…
Abstract Number: 2141 • ACR Convergence 2023
Glucocorticoid Treatment in Early Rheumatoid Arthritis Is Associated with Increased Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) Levels: A Post-hoc Analysis of a Randomized Controlled Trial (NORD-STAR)
Kristina Lend¹, Jos W.R. Twisk², Nupur Kumar³, John Lampa⁴, Anna Rudin⁵, Merete Hetland⁶, Till Uhlig⁷, Dan Nordstrom⁸, Mikkel Østergaard⁹, Marte Schrumpf Heiberg¹⁰, Espen A Haavardsholm¹⁰, Bjorn Gudbjornsson¹¹, Tuulikki Sokka-Isler¹², Gerdur Maria Grondal¹³, Kim Hørslev-Petersen¹⁴, Michael Nurmohamed², Ronald van Vollenhoven² and Johan Frostegård³, ¹Amsterdam UMC, Karolinska Institute, Stockholm, Sweden, ²Amsterdam University Medical Centers, Amsterdam, Netherlands, ³Karolinska Institutet, Stockholm, Sweden, ⁴Stockholm County, Hãsselby, Sweden, ⁵Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁶Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ⁷Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ⁸Helsinki University Hospital, Helsinki, Finland, ⁹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, ¹⁰Diakonhjemmet Hospital, Oslo, Norway, ¹¹Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ¹²Jyvaskyla Central Hospital, Jyväskylä, Finland, ¹³Department for Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, ¹⁴University of Southern Denmark, Odense, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is associated with an elevated risk for developing atherosclerotic cardiovascular disease (CVD). Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key…
Abstract Number: 2157 • ACR Convergence 2023
Exploratory Analysis of the Mechanisms of Action of the Potential Analgesic Effect of Tofacitinib and Adalimumab over Placebo in Patients with Rheumatoid Arthritis: Results of a Mediation Modeling Analysis
Maxime Dougados¹, Peter C. Taylor², David Gruben³ and Meriem Kessouri⁴, ¹Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris, Paris, France, ²Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ³Pfizer Inc., Groton, CT, ⁴Pfizer Inc., Paris, France
Background/Purpose: Pain is the most common symptom reported by patients (pts) with rheumatic disorders, such as RA.1 Improvement in pain with antirheumatic drugs is generally…
Abstract Number: 2174 • ACR Convergence 2023
JAK Inhibitors in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 73 Patients, 55 of Baricitinib
Ana Serrano-Combarro¹, Belén Atienza-Mateo², Jesus Alejandro Valero-Jaimes³, Marta Pastor-Mena⁴, Rafael Benito Melero-Gonzalez⁵, David Castro-Corredor⁶, Maria Martin-Lopez⁷, Santos Castañeda⁸, Jesus Loarce-Martos⁹, Natalia Mena Vazquez¹⁰, Carmen carrasco-Cubero¹¹, Carolina Diez-Morrondo¹², andrea Garcia-Valle¹³, Gema Bonilla¹⁴, Juan Maria Blanco-Madrigal¹⁵, Natividad del Val del Amo¹⁶, Nuria Vegas Revenga¹⁷, Lorena Perez-Albadalejo¹⁸, Rafaela Ortega Castro¹⁹, Deseada Palma-Sanchez²⁰, Ana Maria fernandez-Ortiz²¹, Patricia Lopez-Viejo²², Maria Lopez-Lasanta²³, Marta Garijo Bufort²⁴, Ivette Casafont-Sole²⁵, Olga Maiz-Alonso²⁶, Juan Moreno-Morales²⁷, Ana Urruticoechea²⁸, Carolina Perez-Garcia²⁹, Jose Rosas³⁰, Virginia Ruiz-Esquide³¹, Delia Fernández-Lozano³², Ignacio Brana Abascal³³, Evelin Cecilia Cervantes-Perez³⁴, Julia Fernandez-Melon³⁵, Cristina Fernandez³⁶, Bryan Josue Flores Robles³⁷, Diego Ferrer³⁸ and Ricardo Blanco³⁹, ¹Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Spain, ²Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Hospital Bidasoa, Irún, Spain, ⁴Hospital de Jerez de la Frontera, Cádiz, Spain, ⁵CHU Vigo, O Carballino, Spain, ⁶General University Hospital of Ciudad Real, Santa Cruz de Mudela (Ciudad Real), Spain, ⁷Hospital 12 de Octubre, Madrid, Spain, ⁸Hospital Universitario de la Princesa, Madrid, Spain, ⁹Ramón y Cajal University Hospital, Madrid, Spain, ¹⁰IBIMA, Málaga, Spain, ¹¹Department of Rheumatology, Hospital Universitario de Badajoz, Badajoz, Spain, ¹²Division of Rheumatology, Hospital de León, León, Spain, ¹³Division of Rheumatology, Complejo Asistencial Universitario de Palencia, Palencia, Spain, ¹⁴Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, ¹⁵Division of Rheumatology, H. Universitario de Basurto, Bilbao, Spain, ¹⁶Complejo Hospitalario de Navarra, Pamplona, Spain, ¹⁷Hospital Galdakao- Usansolo, Galdakao, Spain, ¹⁸Division of Rheumatology, Hospital Universitario de Jaén, Jaén, Spain, ¹⁹Hospital Reina Sofía, Cordoba, Spain, ²⁰Hospital Rafael Mendez, Lorca, Spain, ²¹CHU Badajoz, Badajoz, Spain, ²²Division of Rheumatology, Hospital Severo Ochoa, Leganéz, Spain, ²³Hospital Universitari Vall d'Hebron, Rheumatology, Barcelona, Spain, ²⁴H. de Sagunto, Valencia, Italy, ²⁵Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²⁶University Hospital Donostia, San Sebastian, Spain, ²⁷Hospital Universitario Santa Lucia Cartagena, Cartagena, Spain, ²⁸Hospital Can Misses, Ibiza, Spain, ²⁹Hospital del Mar, Barcelona, Spain, ³⁰Hospital Marina Baixa, Alicante, Spain, ³¹Hospital Clinic, Rheumatology, Barcelona, Spain, ³²Hospital de Mérida, Merida, Spain, ³³Division of Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain, ³⁴Complexo Hospitalario Universitario de Pontevedra, Pontevedra, Spain, ³⁵Division of Rheumatology, Hospital Universitario Son Espases, Palma de Mallorca, Spain, ³⁶Hospital Universitario San Juan de Alicante, Alicante, Spain, ³⁷Hospital Universitario San Pedro, Logroño, Spain, ³⁸Division of Pneumology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³⁹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept and Rituximab are the recommended drugs. JAK inhibitors (JAKi) have…
Abstract Number: 2471 • ACR Convergence 2023
Higher Pain and Functional Impairment in Erosive Hand Osteoarthritis Than in Treated Rheumatoid Arthritis: A Comparative Study Between DIGICOD and ESPOIR Cohorts
Sabryne Berkani¹, Ainhoa Aparicio Monforte², Sophie tuffet², alexandra rousseau², nathalie rincheval³, emmanuel maheu⁴, bernard combe³, Alain SARAUX⁵, Bruno Fautrel⁶, Laure Gossec⁷, Francis Berenbaum⁴, Jeremie SELLAM⁶ and alice courties⁴, ¹Sorbonne Université, Rheumatology department, (AP-HP) Saint-Antoine Hospital, Paris, France, ²Department of Clinical Pharmacology and Clinical Research Platform Paris-East (URCEST-CRC-CRB), APHP, Hôpital St Antoine, Paris, France, ³Department of Rheumatology, University of Montpellier, Montpellier, France, ⁴Sorbonne Université Assistance Publique – Hôpitaux de Paris (AP-HP), Saint-Antoine Hospital, Department of Rheumatology, Paris, France, ⁵CHU Brest, Brest, France, ⁶Sorbonne Université APHP, Paris, France, ⁷Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France
Background/Purpose: Hand osteoarthritis (HOA) is considered as a less severe disease with a better functional prognosis and a lower global burden than rheumatoid arthritis (RA).…
Abstract Number: 2544 • ACR Convergence 2023
Microbial Metabolism of Methotrexate Contributes to Its Pharmacokinetics in Vivo
Diego Orellana, Mohana Mukherjee, Moriah Sandy, Peter Turnbaugh and Renuka Nayak, University of California San Francisco, San Francisco, CA
Background/Purpose: Methotrexate (MTX) is a first-line treatment drug used in rheumatoid arthritis (RA) patients. However, only 30-40% of patients tolerate the drug and achieve adequate…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].